共 129 条
[1]
Furst DE(2010)The risk of infections with biologic therapies for rheumatoid arthritis Semin Arthritis Rheum 39 327-346
[2]
Ramiro S(2017)Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis Ann Rheum Dis 76 1101-1136
[3]
Sepriano A(2008)Vaccination in patients with chronic rheumatic or autoimmune diseases Clin Infect Dis 46 1459-1465
[4]
Chatzidionysiou K(2016)2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis Arthritis Care Res (Hoboken) 68 1-25
[5]
Nam JL(2016)Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older--United States, 2016 Ann Intern Med 164 184-194
[6]
Smolen JS(2014)Vaccinations for rheumatoid arthritis Curr Rheumatol Rep 16 431-5307
[7]
van der Heijde D(2010)Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050 J Immunol 184 5298-170
[8]
Dougados M(2013)JAKs and STATs in immunity, immunodeficiency, and cancer N Engl J Med 368 161-95
[9]
Glück T(2017)Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study Ann Rheum Dis 76 88-1252
[10]
Müller-Ladner U(2016)Baricitinib in patients with refractory rheumatoid arthritis N Engl J Med 374 1243-517